Shattuck Labs(STTK) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights – Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, November 14, 2024 – Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics tar ...